M
Masaaki Nakayama
Researcher at Tohoku University
Publications - 245
Citations - 8900
Masaaki Nakayama is an academic researcher from Tohoku University. The author has contributed to research in topics: Peritoneal dialysis & Kidney disease. The author has an hindex of 40, co-authored 236 publications receiving 7811 citations. Previous affiliations of Masaaki Nakayama include Fukushima University & International University, Cambodia.
Papers
More filters
Journal ArticleDOI
Anemia Management in Peritoneal Dialysis: Perspectives From the Asia Pacific Region.
Philip Kam-Tao Li,Agnes Shin-Man Choy,Sunita Bavanandan,Wei Chen,Marjorie Foo,Talerngsak Kanjanabuch,Yong-Lim Kim,Masaaki Nakayama,Xueqing Yu +8 more
TL;DR: The landscape of treatment of anemia in the PD population in the Asia Pacific region may change in the coming years with the introduction of oral hypoxia-inducible factor prolyl hydroxylase inhibitors into clinical use.
Journal ArticleDOI
Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study.
Kimio Watanabe,Masaaki Nakayama,Tae Yamamoto,Gen Yamada,Hiroshi Sato,Mariko Miyazaki,Sadayoshi Ito +6 more
TL;DR: In this paper, the effect of hyperuricemia on clinical outcomes in CKD patients varies according to the underlying disease causing CKD, and allopurinol did not decrease the risks for renal and non-renal outcomes.
Journal ArticleDOI
Is encapsulating peritoneal sclerosis a threatening issue in continuous ambulatory peritoneal dialysis? The Japanese experience.
Masaaki Nakayama,Masato Ikeda,Naohiko Katoh,Keitaro Yokoyama,Hiroyasu Yamamoto,Yoshindo Kawaguchi,Tatsuo Hosoya,Hideharu Mukai +7 more
TL;DR: Treatment alternatives for EPS include total parenteral nutrition, prednisolone administration, and surgical approaches, all of which have varying success rates, and additional therapeutic and new preventive measures have to be established for EPS.
Book ChapterDOI
Translational Research of Peritoneal Dialysis Solution with Dissolved Molecular Hydrogen.
Masaaki Nakayama,Kimio Watanabe,Yoshimitsu Hayashi,Hiroyuki Terawaki,Wan Jun Zhu,Shigeru Kabayama,Sadayoshi Ito +6 more
TL;DR: H2-enriched PDS is a candidate novel PDS with improved biocompatibility for peritoneal membrane preservation and enhanced mesothelial regeneration by H2, and support the significance of H2-PD clinical trials in the future.
Journal ArticleDOI
Rosuvastatin pretreatment suppresses distant organ injury following unilateral renal ischemia‐reperfusion in hypertensive Dahl salt‐sensitive rats
TL;DR: The effect of rosuvastatin (RO) on the contralateral kidney following unilateral renal I/R is investigated to clarify whether statins could suppress DOI.